OM:BIOA BBiotechs
BioArctic (OM:BIOA B) Stock Confronts Leqembi Dependence After Profit Reversal
BioArctic stock comes into this earnings print with a flat month, a weak 7 day stretch and a 90 day slide that has chipped away at recent enthusiasm. The market has cooled on the story just as the Q2 numbers land.
The headline is simple. A biotech built on rich Leqembi royalty expectations has just posted a small quarterly loss despite SEK 247.5m in revenue and recurring royalties closing in on SEK 200m per quarter. The main question now is how investors price a profit wobble in a business...